View AMCP comments to the CMS’s Advance Notice of Methodological Changes for Calendar Year (CY) 2026 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies
View AMCP comments to the CMS’s Draft CY 2026 Part D Redesign Program Instructions.
View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda.
AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda.
AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda.
Press Release: DA’s Proposed Guidance That Would Reclassify Insulin as a Biologic
